PE20091024A1 - Anticuerpos monoclonales que se unen a anexelekto y sus usos - Google Patents

Anticuerpos monoclonales que se unen a anexelekto y sus usos

Info

Publication number
PE20091024A1
PE20091024A1 PE2008001927A PE2008001927A PE20091024A1 PE 20091024 A1 PE20091024 A1 PE 20091024A1 PE 2008001927 A PE2008001927 A PE 2008001927A PE 2008001927 A PE2008001927 A PE 2008001927A PE 20091024 A1 PE20091024 A1 PE 20091024A1
Authority
PE
Peru
Prior art keywords
anexelekto
monoclonal antibodies
antibodies binding
axl
cdr2
Prior art date
Application number
PE2008001927A
Other languages
English (en)
Inventor
Takehisa Kitazawa
Tsukasa Suzuki
Shigehisa Nagahashi
Hajime Miyamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40638811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20091024A1 publication Critical patent/PE20091024A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDO A UN ANTICUERPO MONOCLONAL QUIMERICO O HUMANIZADO, QUE SE UNE A FND1 DE AXL, QUE COMPRENDE CADENAS PESADAS CDR1, CDR2 Y CDR3 DE SEQ ID Nº 4, 5 Y 6 RESPECTIVAMENTE Y CADENAS LIVIANAS CDR1, CDR2 Y CDR3 DE SEQ ID Nº 8, 9 Y 10 RESPECTIVAMENTE, AMBAS CON SUSTITUCION, SUPRESION, INSERCION Y/O ADICION DE UNO O MAS AMINOACIDOS. DICHO ANTICUERPO INHIBE LA ANGIOGENESIS, SUPRIME EL CRECIMIENTO DE CELULAS CANCEROSAS, INDUCEN E INHIBEN LA FOSFORILACION DE AXL Y ES ANTICANCERIGENO
PE2008001927A 2007-11-15 2008-11-14 Anticuerpos monoclonales que se unen a anexelekto y sus usos PE20091024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007297168 2007-11-15

Publications (1)

Publication Number Publication Date
PE20091024A1 true PE20091024A1 (es) 2009-08-12

Family

ID=40638811

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001927A PE20091024A1 (es) 2007-11-15 2008-11-14 Anticuerpos monoclonales que se unen a anexelekto y sus usos

Country Status (18)

Country Link
US (2) US9175091B2 (es)
EP (2) EP2853544A1 (es)
JP (2) JP5554993B2 (es)
KR (1) KR101568051B1 (es)
CN (1) CN101918452A (es)
AR (1) AR069333A1 (es)
AU (1) AU2008321835B2 (es)
BR (1) BRPI0820543A2 (es)
CA (1) CA2706549A1 (es)
CL (1) CL2008003416A1 (es)
IL (1) IL205545A0 (es)
MX (1) MX2010005397A (es)
PE (1) PE20091024A1 (es)
RU (1) RU2559530C2 (es)
SG (1) SG188134A1 (es)
TW (1) TW200936160A (es)
WO (1) WO2009063965A1 (es)
ZA (1) ZA201003496B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
SG193868A1 (en) 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
JP5554993B2 (ja) 2007-11-15 2014-07-23 中外製薬株式会社 Anexelektoに結合するモノクローナル抗体、およびその利用
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
MA33405B1 (fr) 2009-05-15 2012-07-03 Chugai Pharmaceutical Co Ltd Anticorps anti-axl
TW201106972A (en) 2009-07-27 2011-03-01 Genentech Inc Combination treatments
RU2577986C2 (ru) 2010-06-18 2016-03-20 Дженентек, Инк. Антитела против axl и способы их применения
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
JP6120833B2 (ja) * 2011-06-22 2017-04-26 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) 抗Axl抗体及びその使用
US9249228B2 (en) 2011-06-22 2016-02-02 Oribase Pharma Anti-Axl antibodies and uses thereof
EP2589609A1 (en) * 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
US20150252370A1 (en) * 2014-03-04 2015-09-10 Academia Sinica Use of atx inhibitors for treatment or prevention of influenza virus a infections
GB201410826D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
GB201410825D0 (en) 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
IL296633A (en) 2014-07-11 2022-11-01 Genmab As Antibodies that bind axl
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
WO2016091891A1 (en) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies against axl
AU2015366213B2 (en) 2014-12-18 2021-10-07 Bergenbio Asa Anti-Axl antagonistic antibodies
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
ME03772B (me) 2015-07-10 2021-04-20 Genmab As Konjugati antitijela specifičnog za axl i lijeka za liječenje kancera
CN108291669B (zh) * 2015-12-03 2019-10-11 三菱电机株式会社 封闭用弹性体、空调装置及封闭方法
EP3402465B1 (en) 2016-01-13 2024-03-13 Genmab A/S Formulation for antibody and drug conjugate thereof
TWI844509B (zh) 2016-05-13 2024-06-11 美商拜奧亞特拉公司 抗-ror2抗體、抗體片段、其免疫結合物及其用途
GB201610902D0 (en) 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Axlまたはror2に対するキメラ抗原受容体およびその使用方法
BR112019021880A2 (pt) 2017-04-20 2020-06-02 Adc Therapeutics Sa Terapia de combinação com conjugado anticorpo anti-axl-droga
CN112218895A (zh) 2018-04-10 2021-01-12 健玛保 用于癌症治疗的axl特异性抗体
CN110540592B (zh) * 2018-05-29 2022-08-09 杭州尚健生物技术有限公司 结合axl蛋白的抗体及其应用
US20220273809A1 (en) 2019-07-19 2022-09-01 Genmab A/S Axl antibody-drug conjugates for use in treating cancer
GB201912059D0 (en) 2019-08-22 2019-10-09 Bergenbio As Combaination therapy of a patient subgroup
CN110982791A (zh) * 2019-12-26 2020-04-10 百泰生物药业有限公司 一种分泌axl抗体的杂交瘤细胞的制备筛选方法
AR121441A1 (es) 2020-02-28 2022-06-08 Symphogen As Anticuerpos anti-axl y composiciones
GB202004189D0 (en) 2020-03-23 2020-05-06 Bergenbio As Combination therapy
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
GB202006072D0 (en) 2020-04-24 2020-06-10 Bergenbio Asa Method of selecting patients for treatment with cmbination therapy
GB202104037D0 (en) 2021-03-23 2021-05-05 Bergenbio Asa Combination therapy
CN116063535B (zh) * 2022-09-14 2023-09-26 北京市疾病预防控制中心 一种抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1990003400A1 (en) * 1988-09-28 1990-04-05 Dana-Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
US5468624A (en) * 1993-07-02 1995-11-21 Board Of Regents, The University Of Texas System Cell lysis activity of a modified fragment of the glucocorticoid receptor
EP0730646A1 (en) 1993-11-23 1996-09-11 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
AU2003242024A1 (en) 2002-06-05 2003-12-22 Chugai Seiyaku Kabushiki Kaisha Method of constructing antibody
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003286746A1 (en) 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
EP1572103A4 (en) * 2002-11-15 2008-02-13 Centocor Inc ANTI-ANGIOGENIC USES OF IL-6 ANTAGONISTS
JP2008501624A (ja) * 2003-11-18 2008-01-24 アテニュオン, エルエルシー ウロキナーゼのアミノ末端断片と結合する抗体および/または抗体コンジュゲート、その組成物ならびに使用
EP1922310A2 (en) 2005-09-07 2008-05-21 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
EP1789435B1 (en) * 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
CA2641026A1 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
HUE029635T2 (en) 2007-09-26 2017-03-28 Chugai Pharmaceutical Co Ltd A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR
CN101939336B (zh) 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
JP5554993B2 (ja) 2007-11-15 2014-07-23 中外製薬株式会社 Anexelektoに結合するモノクローナル抗体、およびその利用
MA33405B1 (fr) 2009-05-15 2012-07-03 Chugai Pharmaceutical Co Ltd Anticorps anti-axl

Also Published As

Publication number Publication date
CA2706549A1 (en) 2009-05-22
ZA201003496B (en) 2011-08-31
BRPI0820543A2 (pt) 2015-06-16
AR069333A1 (es) 2010-01-13
AU2008321835A1 (en) 2009-05-22
SG188134A1 (en) 2013-03-28
JPWO2009063965A1 (ja) 2011-03-31
KR101568051B1 (ko) 2015-11-10
JP2014224116A (ja) 2014-12-04
EP2228392A1 (en) 2010-09-15
RU2559530C2 (ru) 2015-08-10
WO2009063965A1 (ja) 2009-05-22
US20160053019A1 (en) 2016-02-25
CN101918452A (zh) 2010-12-15
US9175091B2 (en) 2015-11-03
US20110044984A1 (en) 2011-02-24
MX2010005397A (es) 2010-10-04
CL2008003416A1 (es) 2009-10-30
EP2853544A1 (en) 2015-04-01
JP5554993B2 (ja) 2014-07-23
RU2010123916A (ru) 2011-12-20
AU2008321835B2 (en) 2014-11-20
TW200936160A (en) 2009-09-01
IL205545A0 (en) 2010-12-30
EP2228392A4 (en) 2012-05-02
KR20100097688A (ko) 2010-09-03

Similar Documents

Publication Publication Date Title
PE20091024A1 (es) Anticuerpos monoclonales que se unen a anexelekto y sus usos
ES2523194T3 (es) Anticuerpo monoclonal humano específico para cada tumor
CO6251371A2 (es) Un anticuerpo anti-cd37 derivado de un anticuerpo monoclonal murino
RS53760B1 (en) HUMAN ANTIBODIES RELATING TO MESOTELINE AND THEIR USES
PE20191546A1 (es) Moleculas de union antigeno biespecificas que comprenden el clon 20h4.9 anti-41bb
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
RS54624B1 (en) MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
PE20130479A1 (es) Anticuerpos reactivos con b7-h3, fragmentos inmulogicamente activos de los mismos y usos de los mismos
PE20241349A1 (es) Anticuerpos de union a cd3
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
BRPI0811526A2 (pt) uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
MX2022010487A (es) Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos.
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
NZ600262A (en) Anti-her3 antibodies and uses thereof
ES2683847T3 (es) Inmunoglobulina citotóxica

Legal Events

Date Code Title Description
FC Refusal